Clinical Utility of Procalcitonin in The Prediction of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus
Hamdy, H., Ghoneim, W., Abdelmonem, H., Ali, I., Emam, M. (2016). Clinical Utility of Procalcitonin in The Prediction of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus. EKB Journal Management System, 65(1), 479-490. doi: 10.12816/0033756
Hanaa Hamdy; Wafaa Ghoneim; Hatem Abdelmonem; Ibrahim Ali; Marwa Emam. "Clinical Utility of Procalcitonin in The Prediction of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus". EKB Journal Management System, 65, 1, 2016, 479-490. doi: 10.12816/0033756
Hamdy, H., Ghoneim, W., Abdelmonem, H., Ali, I., Emam, M. (2016). 'Clinical Utility of Procalcitonin in The Prediction of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus', EKB Journal Management System, 65(1), pp. 479-490. doi: 10.12816/0033756
Hamdy, H., Ghoneim, W., Abdelmonem, H., Ali, I., Emam, M. Clinical Utility of Procalcitonin in The Prediction of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus. EKB Journal Management System, 2016; 65(1): 479-490. doi: 10.12816/0033756

Clinical Utility of Procalcitonin in The Prediction of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus

The Egyptian Journal of Hospital Medicine
Article 4, Volume 65, Issue 1, October 2016, Page 479-490  XML PDF (475.1 K)
Document Type: Original Article
DOI: 10.12816/0033756
View on SCiNiTO View on SCiNiTO
Authors
Hanaa Hamdy1; Wafaa Ghoneim2; Hatem Abdelmonem2; Ibrahim Ali3; Marwa Emam3
1Hormones Department,National Research Center
2Biochemistry Departments, Faculty of Science
3Biochemistry Department, National Institute of Diabetes and Endocrinology
Abstract
Objective:this study was initiated to assess procalcitoninas prognostic marker forcardiovascular complication in type2 diabetic patients.
Subjects and methods:forty  type 2 diabetic patients without cardiovascular disease, forty  type 2 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in the present study. Serum procalcitoninlevels were assayed and correlated with metabolic parameters.ROC curve analysis was also done for this biochemical marker.
Results:the mean level of procalcitonin was 707.17± 99.19ng/l in diabetic subjects versus 881.30± 123.56ng/l for the cardio-diabetic subjects (P < 0.0001).Procalcitonin levels were significantly amplified in the cardio-diabetic patients with increasing C-reactive protein (CRP), triglycerides (TG), fasting blood glucose (FBG),and cholesterol (P = 0.004, 0.0005, 0.002 and 0.01 respectively). From ROC curve analysis, it was observed that the area under curve for procalcitoninwas 0.878. This finding indicates the good validity of the above biomarker as aprognostic factor for cardiovascular complication in type 2 diabetic patients.
Conclusion:this study evidences the usefulness of measuring serum levels of procalcitoninin diagnosis of cardiovascular complication in type 2 diabetic patients.
 
Keywords
Procalcitonin; Diabetes mellitus; Cardiovascular complications; prognosis
Statistics
Article View: 189
PDF Download: 321